Tozorakimab (MEDI3506): a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction
E. England, D. G. Rees, I. C. Scott, S. Carmen, D. T. Y. Chan, C. E. C. Huntington, K. F. Houslay, T. Erngren, M. Penney, J. B. Majithiya, L. Rapley, D. A. Sims, C. Hollins, E. C. Hinchy, M. D. Strain, , E. S. Cohen
This paper describes tozorakimab, an anti-IL-33 antibody that inhibits both reduced and oxidized IL-33 signaling pathways to reduce inflammation and epithelial dysfunction.
bioRxiv · Feb 28, 2023Immunology